Nieves Martinez Lago: FDA approvals Tumor-Agnostic drugs

Nieves Martinez Lago: FDA approvals Tumor-Agnostic drugs

Nieves Martinez Lago, Medical Oncologist at University Hospital Complex of Ferrol, shared on X/Twitter:

“FDA approvals Tumor-Agnostic drugs:

  1. dMMR
  2. Pembrolizumab 2017
  3. Dostarlimab 2022
  4. MSI-H
  5. Pembrolizumab 2017
  6. TMB-High
  7. Pembrolizumab 2020
  8. NTRK fusions
  9. Larotrectinib 2018
  10. Entrectinib 2019
  11. BRAF V600E
  12. Dabrafenib + Trametinib 2022
  13. RET fusions
  14. Selpercatinib 2022
  15. HER2 3+
  16. T-derutxecan 2024.”

Source: Nieves Martinez Lago/X

BRAF V600E cancer dabrafenib dMMR Dostarlimab Drugs Entrectinib HER2 3+ larotrectinib MSI-H NTRK fusions OncoDaily Oncology pembrolizumab RET fusions Selpercatinib T-derutxecan TMB-High Trametinib Tumor-agnostic University Hospital Complex of Ferrol